vilanterol trifenatate

FDA Drug Profile

Drug Details

Generic Name
vilanterol trifenatate
Brand Names
N/A
Application Number
Sponsor
Glaxo Wellcome Manufacturing Pte. Ltd
NDC Codes
2
Dosage Forms
POWDER
Routes
N/A
Active Ingredients
VILANTEROL TRIFENATATE

Indications and Usage

1 INDICATIONS AND USAGE Umeclidinium and Vilanterol ELLIPTA is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Limitations of Use Umeclidinium and Vilanterol ELLIPTA is NOT indicated for the relief of acute bronchospasm or for the treatment of asthma. The safety and effectiveness of Umeclidinium and Vilanterol ELLIPTA in asthma have not been established. Umeclidinium and Vilanterol ELLIPTA is a combination of umeclidinium, an anticholinergic, and vilanterol, a long-acting beta 2 -adrenergic agonist (LABA), indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). ( 1 ) Limitations of Use: Not indicated for relief of acute bronchospasm or for the treatment of asthma. ( 1 , 5.2 )